NCT05357807

Brief Summary

The Roux-en-Y gastric bypass (RYGB) has proven to be an effective treatment for morbid obesity by reducing weight and comorbidities. Extending the pouch may improve weightloss without the increase of complications. Some patients regain weight after initially good weightloss. Placing a minimizer around the pouch may prevent weight regain.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
375

participants targeted

Target at P75+ for not_applicable

Timeline
21mo left

Started Mar 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress75%
Mar 2021Mar 2028

Study Start

First participant enrolled

March 1, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 25, 2021

Completed
11 months until next milestone

First Posted

Study publicly available on registry

May 3, 2022

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
4.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2028

Expected
Last Updated

June 21, 2024

Status Verified

June 1, 2024

Enrollment Period

2.3 years

First QC Date

May 25, 2021

Last Update Submit

June 19, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage Total Body Weight Loss (%TBWL)

    ((preoperative weight - current weight) / (preoperative weight)) x 100%. Weight loss measured in kilograms

    3 years

Secondary Outcomes (6)

  • Percentage Excess Weight Loss (%EWL)

    3 years

  • BODY-Q: Quality of life after bariatric surgery

    3 years

  • BAROS: Quality of life after bariatric surgery

    3 years

  • SF-36: Quality of life after bariatric surgery

    3 years

  • Gastroesophageal reflux disease

    3 years

  • +1 more secondary outcomes

Study Arms (3)

Standard RYGB

ACTIVE COMPARATOR

127 patients undergo a standard Roux-en-Y gastric bypass

Procedure: Standard RYGB

Extended Pouch RYGB

EXPERIMENTAL

127 patients undergo a Roux-en-Y gastric bypass with an extended pouch.

Procedure: Extended Pouch RYGB

Banded Extended RYGB

EXPERIMENTAL

127 patients undergo a Roux-en-Y gastric bypass with a minimizer around the extended pouch.

Procedure: Banded extended pouch RYGB

Interventions

Standard RYGBPROCEDURE

Roux-en-Y Gastric bypass

Also known as: S-RYGB
Standard RYGB

Roux-en-Y gastric bypass with an extended pouch

Also known as: EP-RYGB
Extended Pouch RYGB

Roux-en-Y gastric bypass with a banded extended pouch

Also known as: BEP-RYGB
Banded Extended RYGB

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients who are eligible for a primary RYGB

You may not qualify if:

  • Bariatric surgery in medical history
  • Patients with a language barrier which may affect the compliance with medical advice
  • Patients with a disease not related to morbid obesity, such as Cushing or drug related.
  • Chronic bowel disease for example Crohn's disease or colitis Colitis.
  • Renal impairment (MDRD \<30)
  • Hepatic dysfunction (liver function twice the normal values)
  • Pregnancy during follow-up
  • Patients with treatment-resistant reflux symptoms.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Rijnstate Hospital

Arnhem, Gelderland, 6815AD, Netherlands

Location

St. Antonius Ziekenhuis

Nieuwegein, Utrecht, 3435CM, Netherlands

Location

NOK West

The Hague, Netherlands

Location

MeSH Terms

Conditions

Obesity, Morbid

Condition Hierarchy (Ancestors)

ObesityOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 25, 2021

First Posted

May 3, 2022

Study Start

March 1, 2021

Primary Completion

June 1, 2023

Study Completion (Estimated)

March 1, 2028

Last Updated

June 21, 2024

Record last verified: 2024-06

Locations